[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612041":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":22,"locations":22,"responsibleParty":34,"collaborators":36,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":22,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":22,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":22},{"fullName":5,"class":6},"Liverpool School of Tropical Medicine","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Diagnostic","Diagnostic Test - all participants",[12,13,14,15],"Diagnostic Test: Xpert MTB\u002FRIF Ultra","Diagnostic Test: Truenat, MTB","Diagnostic Test: Truenat MTB Plus","Diagnostic Test: TB LAMP",[17,23,27,30],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DIAGNOSTIC_TEST","Xpert MTB\u002FRIF Ultra","automated molecular test",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Truenat, MTB","Micro-Polymerase Chain Reaction (PCR) diagnostic test",[9],{"type":18,"name":28,"description":25,"armGroupLabels":29,"otherNames":22},"Truenat MTB Plus",[9],{"type":18,"name":31,"description":32,"armGroupLabels":33,"otherNames":22},"TB LAMP","manual molecular test",[9],{"type":35,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[37,40,42,44],{"name":38,"class":39},"Centre for Control of Chronic Disease (CCCD),icddr,b","UNKNOWN",{"name":41,"class":39},"Comité National d'Ethique pour la Recherche en Santé Humaine",{"name":43,"class":6},"KEMRI-Wellcome Trust Collaborative Research Program",{"name":45,"class":39},"National Lung Hospital, Vietnam","100612041","start-taking-action-for-tuberculosis-in-kids-100612041",false,"NCT07248423","Start Taking Action for Tuberculosis in Kids","Evaluating the Performance, Feasibility, Acceptability and Cost Effectiveness of Concurrent Testing Including Novel Diagnostics, Non-sputum Specimens and Computer-aided Detection Interpretation of Chest X-ray for Childhood Tuberculosis in Bangladesh, Cameroon, Kenya and Viet Nam.","Start4Kids","Inclusion Criteria:\n\n1. Age 14 and below on the day of assessment\n2. Fulfils the criteria of presumptive TB according to the definition 10.1 of the protocol, or TB associated risk factors according to the definition 10.2. of the protocol\n3. Diagnosed with TB disease\n\nExclusion Criteria:\n\n1. On treatment for TB disease at the time of evaluation\n2. Parent or guardian does not allow the child to participate in the study or declines to sign the ICF.\n3. The child does not wish to participate in the study or declines to sign the Assent Form (where applicable)",true,"ALL","0 Years","15 Years",{"count":59,"type":60},7920,"ESTIMATED","INTERVENTIONAL",[63],"NA","Start4Kids: Evaluating the performance, feasibility, acceptability and cost effectiveness of computer-aided detection (CAD) of chest X-ray (CXR) and concurrent testing using novel diagnostics and non-sputum specimens for childhood tuberculosis (TB) in Bangladesh, Cameroon, Kenya and Viet Nam.",[66],"TB - Tuberculosis",[68,69],"TB","Diagnostics","NOT_YET_RECRUITING","2025-11-18",{"date":73,"type":74},"2025-11-25","ACTUAL",{"date":76,"type":60},"2026-03-01",{"date":78,"type":60},"2027-10-01",{"name":5,"class":6}]